45 results about "Fetal protein" patented technology

The invention discloses a preparation method of an unlabelled photoelectrochemical alpha fetoprotein immunosensor, and belongs to the fields of novel nano functional materials and biosensors. On the basis of a titanium dioxide nano particle base, a trimetal alloy nano material in a dendrite nanorod form is prepared by a photoelectrochemical synthetic method, so that the prepared unlabelled photoelectrochemical alpha fetoprotein immunosensor for detecting alpha fetal protein is low in cost, high in sensitivity, good in specificity, fast in detection and simple to prepare.

The invention relates to the field of biological detection, and particularly relates to a detection kit for quantitatively detecting AFP (alpha fetal protein) and a preparation method and use of the detection kit. The invention provides a detection kit for quantitatively detecting AFP. The detection kit comprises a test paper card, wherein the test paper card comprises a bottom plate, and a sample pad, a gold-marking pad, a nitrocellulose membrane and an absorbent pad which are arranged on the surface of the bottom plate and are sequentially arranged from the loading end; the gold-marking pad comprises an AFP antibody; the nitrocellulose membrane is coated with a detection line and a quality control line; and the AFP antibody on the gold-marking pad is marked by virtue of fluorescent microspheres. The detection kit for quantitatively detecting the AFP, provided by the invention, is used for detecting the AFP through a fluorescent microsphere immune chromatography technology for the first time, has sensitivity and specificity, and has the advantages of being rapid and easy to operate, accurate in result, economical, applicable and the like.

The invention relates to a method for detecting alpha-fetal protein on the basis of an RGO-CS-Fc/Au NPs nano composite material and aptamers. According to the method, the surface of a silk-screen printing electrode is modified with RGO-CS-Fc/Au NPs by means of an electro-deposition technology and an electrostatic adsorption effect; AFP aptamers are loaded on the surface of the RGO-CS-Fc/Au NPs bymeans of a nanotechnology and an intermolecular force, and the aptamers exist on the surface of the composite material in the form of single-chain structures due to the unstable spatial structures ofthe aptamers; after AFP is added into the surface of the electrode, the AFP can be specifically combined with the AFP aptamers, so that stable spatial structures can be generated, and therefore, the AFP and the aptamers can be orderly arranged on the surface of the electrode; a current value is detected through a DPV method, a relation curve of current and the concentration of the alpha-alpha protein is depicted; and therefore, the quantitative detection of the alpha-alpha protein is realized. The method has the advantages of simple operation, time-saving performance, low cost and low detection limit.

The invention discloses an AFP and GM-CSF dual-gene co-expression recombinant vector, which is sequentially linked with an AFP gene, an IRES sequence and a GM-CSF gene in a vector transcription direction, or is sequentially linked with a GM-CSF gene, an IRES sequence and an AFP gene in a vector transcription direction, wherein nucleotide sequence of the AFP gene is represented in SEQ ID NO: 1 in a sequence list, nucleotide sequence of the GM-CSF gene is represented in SEQ ID NO: 2 in the sequence list, and nucleotide sequence of the IRES sequence is represented in SEQ ID NO: 3 in the sequence list. The dual-gene co-expression recombinant vector, which links the AFP gene and the GM-CSF gene through the IRES sequence, can simultaneously express alpha fetal protein and a granulocyte-macrophage colony stimulating factor in a same vector; and the recombinant vector, in immunogene therapy of liver cancer, not only can develop an immune regulating function of a cell factor but also can generate a specific anti-tumor effect targeted for the liver cancer.

The invention discloses an application of DDK1 as a diagnostic marker. Through analysis of a large amount of hepatocellular carcinoma samples, the inventor analyzes the expressions of DKK1 and AFP, firstly discovers that serum DKK1 has a high sensitivity and specificity on diagnosis of hepatocellular carcinoma, especially diagnosis of alpha fetal protein negative hepatocellular carcinoma, identification of hepatocellular carcinoma and alpha fetal protein positive chronic liver disease, and/or diagnosis of hepatocellular carcinoma in the early stage or small hepatocellular carcinoma, and more especially the precision of clinical diagnosis can be largely increased by DKK1-AFP combined diagnosis.

The invention discloses a combined general check protein chip for early-stage cancers mainly comprising lung cancer and belongs to the technical field of a protein chip. The combined general check protein chip for the early-stage cancers mainly comprising the lung cancer, provided by the invention, comprises a chip substrate and marker antibodies distributed on the chip substrate, wherein the chip substrate is an FAST protein chip substrate having a three-dimensional nitrocellulose basic material; one or more sample application module is arranged on the FAST protein chip substrate; the following marker antibodies are fixed on the sample application module: 14-3-3 theta, LAMR-1, TSGF (Tumor Specific Growth Factor), CEA (Cancer Embryo Antigen), SCC (Squamous Cell Carcinoma), CYFRA21-1 and positive control; the following marker antibodies are also fixed: AFP (Alpha Fetal Protein), CA242, MG-Ag, CA199, TPA (Tissue Polypeptide Antigen) and EA-IgA; and the following marker antibodies are further fixed: CA125, CA153, SF (Serum Ferritin) and PSA (Prostate Specific Antigen). According to the combined general check protein chip provided by the invention, the related indexes are highly integrated; the combined general check protein chip has the advantages of excellent stability, strong specificity, long retention period, high sensitivity, excellent repeatability, convenience in operation and low cost; the labor efficiency is increased; and a cancer patient is diagnosed and treated from the general check before clinical symptoms occur.

The invention discloses an application of miR-107 combined with miR-1246 as an early diagnostic marker for hepatocellular carcinoma metastasis. Researches find that miR-107 combined with miR-1246 for diagnosis of early liver cancer metastasis is superior to alpha fetal protein (AFP), and has good sensitivity and specificity, and the miR-107 and miR-1246 combined with AFP diagnosis is more excellent. As to metastasis diagnosis of low alpha fetal protein secretion liver cancer (AFP is smaller than 200), the miR-1246 is superior to the APF, the miR-107 combined with miR-1246 diagnosis is much superior to the APF, and the miR-107 and miR-1246 combined with AFP are more excellent. On the basis, a primer, a kit and a detection method for detecting the miR-107 and the miR-1246 are developed, and the serum microRNA has a good development prospect and clinical application value. A sequence of the primer is shown in SEQ ID NO.3 and 4, and the kit is formed by a specific amplification primer and a required reagent for PCR amplification.

The invention provides a kit for detecting an alpha fetal protein. The kit is operated based on a colloidal gold immunoturbidimetry and comprises a reagent R2, wherein the Reagent R2 is a solution which contains gold nanoparticles marked with alpha fetal protein antibodies. The kit is characterized in that the particle diameters of the contains gold nanoparticles are 62.2-79.1 nomameters; the mass ratio of the contains gold nanoparticles to the alpha fetal protein antibodies is 50:(20-60). The invention also provides a preparation method of the kit. The kit provided by the invention has the characteristics of high sensitivity, high specificity, fastness in reaction and good stability, precipitations can not be generated after reaction, a biochemical analyzer is convenient to clean and the service life of the biochemical analyzer is prolonged.

The invention relates to use of serum markers containing alpha fetal protein (AFP), Golgi protein 73 (GP73) and carcinoembryonic antigen associated cell adhesion molecule 1 (CEACAM1) in diagnosis of liver diseases. Specifically, the invention provides use of reagents containing an associative part of at least one specific binding AFP, an associative part of at least one specific binding GP73 and an associative part of at least one specific binding CECAM1 protein in preparation of kits for diagnosis and/or prognosis of the liver diseases.

The invention relates to an alpha fetal protein (AFP) kit based on an aptamer fluorescent probe, further relates to a method for measuring AFP concentration and reagent composition and components, and belongs to the technical field of medical detection and measurement. The kit mainly comprises the components of red blood cell lysis buffer, a phosphate buffer solution (PBS), an AFP standard and the AFP aptamer fluorescent probe. The AFP concentration is measured through blood sample splitting and mixed egg cultivation in conjunction with a fluorescent spectrophotometer. The alpha fetal protein kit has the advantages of simple sample treatment, easiness and convenience in operation, short detection time, high detection specificity, high flexibility, high detection result repeatability and the like.

The invention discloses an artificial polypeptide capable of inducing bone mesenchymal stem cells to differentiate into hepatic cells and a biological product of such artificial polypeptide. The artificial polypeptide is a polypeptide containing an amino acid sequence shown in formula (IV): LGENQPDAK(Xa)PCFQEDPMA(Xb)GTDCTLMEIWN, (IV), wherein each of Xa and Xb is selected from M, Y, L, V, W or E. Professionals in the field know that a strong ability to induce the bone mesenchymal stem cells to differentiate into the hepatic cells is achieved in case of combination of acidic fibroblast growth factor, hepatocyte growth factor and oncostatin M, and after induced culture for 14 days, alpha fetal protein mRNA and albumin mRNA in the cells are in remarkably positive expression. It is proven that the artificial polypeptide with the same effect is capable of inducing the bone mesenchymal stem cells to differentiate into the hepatic cells, and accordingly the artificial polypeptide can be prepared into the biological product for inducing the bone mesenchymal stem cells to differentiate into the hepatic cells.

The invention relates to the field of biological detection, in particular to a detection kit for quantitatively detecting AFP (Alpha Fetal Protein), Golgi Protein-73GP73 and PIVKA (Protein Induced Vy Vitamin K Absence)-II or an antagonist-II as well as a preparation method and application of the detection kit. The detection kit comprises an AFP detection test paper card, a Golgi Protein-73GP73 detection test paper card and a PIVKA-II detection test paper card which are independent of one another, wherein each detection test paper card comprises a bottom plate, a sample pad, a gold-labeled pad, a nitrocellulose membrane and a water absorbing pad, wherein the sample pad, the gold-labeled pad, the nitrocellulose membrane and the water absorbing pad are positioned on the surface of the bottom plate and are arranged from the sample adding end in sequence. The kit provided by the invention has the benefits that the AFP, the GP73 and the PIVKA-II are firstly detected through a fluorescent microsphere immune chromatography, and both the sensitivity and the specificity are realized; the kit has the advantages of high quickness, simplicity and convenience in operation, accurate results, good economy and applicability and the like.

The invention provides a hepatocellular carcinoma targeting gene expression element AP and applications thereof, and the gene expression element AP has a nucleotide sequence indicated in SEQ ID No.1.After the expression element AP is guided into Alpha-fetoprotein positive tumor cells, the artificial microRNA aiming at DNA polymerase can be expressed in the cell and the expression of the DNA polymerase in the cell can be effectively inhibited, the copy of the DNA in the cell is further affected; the cell cycle of is blocked finally, the multiplication of the AFP positive hepatoma cell is specially inhibited and the expression element AP can be applied to the preparation of the targeting gene curing medicine of AFP (alpha fetal protein) positive liver cancer.

The invention relates to a human cancer marker detection kit and a detection method. The detection kit includes microcarriers, coating antibodies and detection antibodies. There is at least one kind of microcarrier, and the microcarrier has coding information, and the coding information of microcarriers for different human cancer markers is different. Coating antibodies are used to coat microcarriers. Both the coating antibody and the detection antibody are selected from the antibodies of carcinoembryonic antigen, alpha-fetoprotein, prostate specific antigen, tumor antigen 19-9, tumor antigen 125 and tumor antigen 15-3 For at least one of the corresponding human cancer markers, the coating antibody and the detection antibody have different antigen binding sites. The detection kit can be used to detect up to six human cancer markers, thereby enriching the detection results and assisting clinical diagnosis more effectively.

The invention discloses a human serum AFP (Alpha Fetal Protein) negative liver cell cancer detection kit. A combined diagnosis kit is used for combined diagnosis on patients suffering from AFP negative hepatocellular carcinoma by detecting expression amounts of five RNAs (Ribonucleic Acids) of MiR-125b, MiR-205, SPRY4-IT1, GAS5-AS1 and circSMARCA5 in plasma by using a real-time quantitative PCR (Polymerase Chain Reaction) technique. The kit disclosed by the invention has the characteristics of high sensitivity, high specificity and high accuracy, patients suffering from AFP negative hepatocellular carcinoma can be effectively diagnosed, auxiliary diagnosis on early-stage hepatocellular carcinoma can be achieved, the survival rate of the patients can be increased, and the kit has remarkableclinical application values.

The invention relates to the biotechnology field, and discloses a recombinant plasmid, a recombinant virus plasmid, a recombinant virus of tissue specificity directing against hepatoma cells with positive AFP (Alpha Fetal Protein) and application in preparing drugs for treatment of hepatoma with positive AFP. In the invention, DN-PP2Ac expression is regulated by AFpg promoter of tissue specificity of hepatoma, so that DN-PP2Ac specificity is expressed in hepatoma cells with positive AFP, thereby preventing the effect on normal cells and having a good prospect of clinical application.

The invention discloses use of a Smad3 protein in a peripheral blood exosome as a molecular marker for preparing a liver cancer detection kit and the liver cancer detection kit. A research of the invention shows that the Smad3 protein content of an exosome extracted from human peripheral blood is obviously increased in a liver cancer patient; the Smad3 protein used as a tumor marker for diagnosinga liver cancer obtains an area under the ROC curve of 0.888; in combination with an alpha fetal protein for diagnosing the liver cancer, the area under the ROC curve can be up to 0.975; therefore, the Smad3 in the peripheral blood exosome can be independently used as the tumor marker for diagnosing the liver cancer or can be jointed with the alpha fetal protein to be used as the tumor marker fordiagnosing the liver cancer, and also can be used for judging a postoperative recurrence risk of a liver cancer patient.

The invention relates to an application of serum DDK1 in the preparation of a diagnosis reagent for alpha fetal protein negative hepatocellular carcinoma. Through analysis of a large amount of hepatocellular carcinoma samples, the inventor analyzes the expression situations of DKK1 and AFP from the samples, and firstly discovers that serum DKK1 has a high sensitivity and specificity on diagnosis of AFP negative hepatocellular carcinoma.